Merck reported strong revenue and earnings growth driven by key products like KEYTRUDA and GARDASIL, and provided an optimistic full-year outlook. Despite concerns about potential Medicare negotiations, the company's robust performance and strategic investments suggest confidence in continued momentum. The stock is likely to experience a positive impact in the short term.

[1]